- Home
- ALLR vs THAR Comparison
ALLR vs THAR Comparison
Compare ALLR & THAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALLR
- THAR
- Stock Information
- Founded
- ALLR 2004
- THAR 2017
- Country
- ALLR United States
- THAR United States
- Employees
- ALLR N/A
- THAR N/A
- Industry
- ALLR Biotechnology: Pharmaceutical Preparations
- THAR Biotechnology: Pharmaceutical Preparations
- Sector
- ALLR Health Care
- THAR Health Care
- Exchange
- ALLR Nasdaq
- THAR Nasdaq
- Market Cap
- ALLR 4.7M
- THAR 4.0M
- IPO Year
- ALLR N/A
- THAR 2022
- Fundamental
- Price
- ALLR $1.05
- THAR $2.03
- Analyst Decision
- ALLR
- THAR Strong Buy
- Analyst Count
- ALLR 0
- THAR 1
- Target Price
- ALLR N/A
- THAR $17.00
- AVG Volume (30 Days)
- ALLR 2.6M
- THAR 47.8K
- Earning Date
- ALLR 03-07-2025
- THAR 11-07-2024
- Dividend Yield
- ALLR N/A
- THAR N/A
- EPS Growth
- ALLR N/A
- THAR N/A
- EPS
- ALLR N/A
- THAR N/A
- Revenue
- ALLR N/A
- THAR N/A
- Revenue This Year
- ALLR N/A
- THAR N/A
- Revenue Next Year
- ALLR N/A
- THAR N/A
- P/E Ratio
- ALLR N/A
- THAR N/A
- Revenue Growth
- ALLR N/A
- THAR N/A
- 52 Week Low
- ALLR $0.90
- THAR $1.84
- 52 Week High
- ALLR $288.00
- THAR $7.71
- Technical
- Relative Strength Index (RSI)
- ALLR 47.15
- THAR 45.25
- Support Level
- ALLR $0.96
- THAR $1.86
- Resistance Level
- ALLR $1.72
- THAR $2.06
- Average True Range (ATR)
- ALLR 0.17
- THAR 0.11
- MACD
- ALLR 0.01
- THAR -0.00
- Stochastic Oscillator
- ALLR 13.99
- THAR 38.64
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.
About THAR Tharimmune Inc.
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset, known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.